Briefs
Throughout the first half of 2022, we’ve continued to face historic, unprecedented challenges related to the ongoing global pandemic. Life sciences enterprises, and essentially all industries, are grappling with decisions large and small. Priorities for Commercial, Market Access and Medical Affairs organizations in the life sciences industry continue to shift as teams work feverishly to evolve virtual and digital channels to engage with customers, and to sharpen Advanced Analytics. Developing capabilities and skills in new ways of working continue in…
Read Now
White Papers
The pharma industry has seen dramatic shifts in scientific innovation over the last decade with a trend toward orphan markets, personalized medicine, higher priced products and new modalities including cell and gene therapies, oligonucleotides and others. COVID served to further accelerate scientific innovation, driving a near record-breaking number of FDA approvals, astronomical venture capital funding and remarkably rapid development and rollout of ground-breaking products (including anti-virals, novel antibodies and mRNA vaccines). However, as Trinity Life Sciences discussed one year ago,…
Read Now
Briefs
While the vision and goal of patient centricity are clear, today’s leading life science companies are grappling with the complexities of execution: How to take the “idea” of patient centricity and translate it into strategy and tactics – and how to measure results.
Read our new advisory brief to learn more about our model and the concrete actions companies can do to integrate patient centricity into their business decisions.
Complete the form below to access the full brief
By submitting…
Read Now
Scientific Publications
Cremophor EL (CrEL) is a solubilizer used in paclitaxel and is associated with side effects (i.e., hypersensitivity reactions, peripheral neuropathy). Current CrEL-containing therapies require long infusion times (2-4 hours) and pre-medication with steroids to manage these side-effects. However, the holistic burden of CrEL on patients is not well studied. This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life (QoL) implications.
Authors
Diana Brixner, Anke-Peggy Holtorf, Ayesha…
Read Now
Webinars
Available On Demand
Join Trinity Life Sciences for a webinar that explores the findings from our TGaS report entitled, ‘Reimagining Work Models in the Life Sciences: Implications for the Future of Work’. Life sciences companies have been examining policies and addressing how and where employees should work. Many lack objective sources of data to make informed decisions. TGaS led a study with a Commercial Operations department at a pharmaceutical company to help validate or debunk certain industry work-model assumptions.
Are you interested in…
Watch Now
White Papers
The Changing Work Model for Life Sciences.
When considering a work environment that will be sustainable in this new working world, life sciences companies have been examining policies and addressing how and where employees should work though lack objective sources of data to make informed decisions. The life sciences industry as a whole lacks work-model data. Like many organizations globally, certain work-model assumptions need to be validated or debunked. For example,
Employees should be at company headquarters if or when…
Read Now
Scientific Publications
OBJECTIVES: Point of care rapid diagnostic tests (RDTs) have demonstrated accurate and timely diagnosis across decentralized settings, broadening patient access in remote locations and improving pathways to diagnosis. This study aimed to synthesize published and other literature on the clinical, societal, and economic value of RDTs for infectious disease across Asia, Africa, and Latin America.
METHODS: A systematic literature review (SLR) was conducted using PubMed and Embase for publications dated 2017 to 2021 in accordance with PRISMA guidelines using RDT and infectious…
Read Now
Scientific Publications
OBJECTIVES: The European Medicines Agency’s in-vitro diagnostics (IVD) regulation (IVD-R) will roll out over the next 5 years; under IVD-R, Notified Bodies (NBs) will be required to review a larger proportion of IVDs (estimated increase from 8% to 80%). Under IVD-R manufacturers will not only have to demonstrate safety and equivalence of their IVD, but also scientific validity and analytical/clinical performance. Thought papers have hypothesized IVD-R’s impact on development timelines and evidence requirements. Key concerns include delays in approval timelines due…
Read Now
Scientific Publications
OBJECTIVES: As COVID-19 severely restricted patients’ ability to visit care settings in-person, the use of telehealth was impacted; the immediate and enduring impact on telehealth utilization is an unanswered question. This study aimed to identify medical conditions typically treated using telehealth and quantify trends in telehealth utilization through the COVID-19 pandemic.
METHODS: A retrospective analysis was performed using a 10 million-record random sample of patients with telehealth visits (with telehealth defined by CPT codes with telehealth modifiers or place-of-service codes).…
Read Now
Scientific Publications
OBJECTIVES: Cell and gene therapies (CGT) have prompted innovation in the life sciences landscape and captured national attention. However, the real-world use across this therapeutic class is not well quantified. This study aims to evaluate CGT uptake and quantify utilization patterns in the US, from 2015-2021.
METHODS: This study analyzed patient-level US claims data in the Komodo Healthcare Map™, a dataset including longitudinal medical and prescription claims encompassing adjudicated claims of >150 million unique enrollees from the US commercial, Medicare,…
Read Now
